CARGO Therapeutics, Inc. (CRGX)

Market Cap	625.72M
Revenue (ttm)	n/a
Net Income (ttm)	-56.63M
Shares Out	38.67M
EPS (ttm)	-1.46
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	35,179
Open	16.62
Previous Close	15.64
Day's Range	15.90 - 17.24
52-Week Range	13.14 - 17.29
Beta	n/a
Analysts	Strong Buy
Price Target	28.33 (+75.09%)
Earnings Date	n/a

About CRGX

CARGO Therapeutics is a clinical-stage biotechnology company uniquely positioned to advance next generation, potentially curative cell therapies for cancer patients. Our programs, platform technologies, and manufacturing strategy are designed to directly address the limitations of approved chimeric antigen receptor (CAR) T-cell therapies. Our lead program, CRG-022, which we exclusively licensed from the National Cancer Institute, is being studied by Stanford University in a Phase 1 clinical trial in patients with large B-cell lymphoma (LBCL) wh...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Nov 10, 2023
• Employees: 74
• Stock Exchange: NASDAQ
• Ticker Symbol: CRGX

Analyst Forecast

According to 4 analysts, the average rating for CRGX stock is "Strong Buy." The 12-month stock price forecast is $28.33, which is an increase of 75.09% from the latest price.

Price Target

$28.33

(75.09% upside)

Analyst Consensus: Strong Buy